| Literature DB >> 25794182 |
Kelly R Reveles1, Timothy R Juday2, Matthew J Labreche3, Eric M Mortensen4, Jim M Koeller1, Daniel Seekins2, Christine U Oramasionwu5, Mary Bollinger6, Laurel A Copeland7, Xavier Jones6, Christopher R Frei1.
Abstract
This study compared the ability of four measures of patient retention in HIV expert care to predict clinical outcomes. This retrospective study examined Veterans Health Administration (VHA) beneficiaries with HIV (ICD-9-CM codes 042 or V08) receiving expert care (defined as HIV-1 RNA viral load and CD4 cell count tests occurring within one week of each other) at VHA facilities from October 1, 2006, to September 30, 2008. Patients were ≥18 years old and continuous VHA users for at least 24 months after entry into expert care. Retention measures included: Annual Appointments (≥2 appointments annually at least 60 days apart), Missed Appointments (missed ≥25% of appointments), Infrequent Appointments (>6 months without an appointment), and Missed or Infrequent Appointments (missed ≥25% of appointments or >6 months without an appointment). Multivariable nominal logistic regression models were used to determine associations between retention measures and outcomes. Overall, 8,845 patients met study criteria. At baseline, 64% of patients were virologically suppressed and 37% had a CD4 cell count >500 cells/mm3. At 24 months, 82% were virologically suppressed and 46% had a CD4 cell count >500 cells/mm3. During follow-up, 13% progressed to AIDS, 48% visited the emergency department (ED), 28% were hospitalized, and 0.3% died. All four retention measures were associated with virologic suppression and antiretroviral therapy initiation at 24 months follow-up. Annual Appointments correlated positively with CD4 cell count >500 cells/mm3. Missed Appointments was predictive of all primary and secondary outcomes, including CD4 cell count ≤500 cells/mm3, progression to AIDS, ED visit, and hospitalization. Missed Appointments was the only measure to predict all primary and secondary outcomes. This finding could be useful to health care providers and public health organizations as they seek ways to optimize the health of HIV patients.Entities:
Mesh:
Year: 2015 PMID: 25794182 PMCID: PMC4368570 DOI: 10.1371/journal.pone.0120953
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient baseline characteristics.
| Variables | Subcategory | Overall (n = 8,845) | Missed Appointments (n = 5,786) | No Missed Appointments (n = 3,059) | P-value |
|---|---|---|---|---|---|
|
| 52 ± 10 | 51 ± 9 | 54 ± 10 | <0.0001 | |
|
| 8,608 (97%) | 5,597 (97%) | 3,011 (98%) | <0.0001 | |
|
| Black, non-Hispanic | 4,466 (51%) | 3,314 (57%) | 1,152 (38%) | <0.0001 |
| White, non-Hispanic | 3,010 (34%) | 1,624 (28%) | 1,386 (45%) | <0.0001 | |
| Hispanic | 496 (6%) | 364 (6%) | 132 (4%) | <0.0001 | |
| Other, non-Hispanic | 484 (5%) | 260 (4%) | 224 (7%) | <0.0001 | |
|
| 1,225 (14%) | 801 (14%) | 424 (14%) | 0.9825 | |
|
| Suppressed (<500 copies/mL) | 5,612 (64%) | 3,311 (57%) | 2,301 (75%) | <0.0001 |
| Non-suppressed (≥ 500 copies/mL) | 3,233 (37%) | 2,475 (43%) | 758 (25%) | <0.0001 | |
|
| <200 cells/mm3 | 1,937 (22%) | 1,376 (24%) | 561 (18%) | <0.0001 |
| 200–349 cells/mm3 | 1,786 (20%) | 1,202 (21%) | 584 (19%) | 0.0607 | |
| 350–500 cells/mm3 | 1,884 (21%) | 1,218 (21%) | 666 (22%) | 0.4308 | |
| >500 cells/mm3 | 3,238 (37%) | 1,990 (34%) | 1,248 (41%) | <0.0001 | |
|
| Priority 1 | 1,660 (19%) | 1,215 (21%) | 445 (14%) | <0.0001 |
| Priority 2–6 | 6,356 (72%) | 4,259 (74%) | 2,160 (71%) | <0.0001 | |
| Priority 7–8 | 749 (8%) | 302 (5%) | 447 (15%) | <0.0001 | |
|
| 6.6 ± 2.1 | 6.7 ± 2.2 | 6.6 ± 1.9 | 0.0002 | |
|
| Congestive heart failure | 164 (2%) | 119 (2%) | 45 (1%) | 0.0521 |
| Chronic obstructive pulmonary disease | 925 (11%) | 662 (11%) | 263 (9%) | <0.0001 | |
| Cerebrovascular disease | 239 (3%) | 170 (3%) | 69 (2%) | 0.0597 | |
| Diabetes with complications | 176 (2%) | 127 (2%) | 49 (2%) | 0.0574 | |
| Diabetes without complications | 1,098 (12%) | 760 (13%) | 338 (11%) | 0.0047 | |
| Hemi/paraplegia | 33 (0.4%) | 26 (0.4%) | 7 (0.2%) | 0.1056 | |
| HIV (as defined by Charlson) | 2,173 (25%) | 1,512 (26%) | 661 (22%) | <0.0001 | |
| AIDS (as defined by Charlson) | 8,134 (92%) | 5,285 (91%) | 2,849 (93%) | 0.0032 | |
| Liver (mild disease) | 27 (0.3%) | 18 (0.3%) | 9 (0.3%) | 0.8911 | |
| Liver (mod/severe disease; cirrhosis) | 115 (1%) | 75 (1%) | 40 (1%) | 0.9641 | |
| Cancer | 536 (6%) | 341 (6%) | 195 (6%) | 0.3671 | |
| Leukemia | 11 (0.1%) | 8 (0.1%) | 3 (0.1%) | 0.6099 | |
| Metastatic cancer | 27 (0.3%) | 15 (0.3%) | 12 (0.4%) | 0.2807 | |
| Myocardial infarction | 97 (1%) | 64 (1%) | 33 (1%) | 0.9065 | |
| Peptic ulcer disease | 73 (0.8%) | 51 (0.9%) | 22 (0.7%) | 0.4224 | |
| Peripheral vascular disease | 159 (2%) | 112 (2%) | 47 (2%) | 0.1789 | |
| Renal disease | 463 (5%) | 313 (5%) | 150 (5%) | 0.3095 | |
| Dyslipidemia | 2,772 (31%) | 1,506 (26%) | 1,266 (41%) | <0.0001 | |
| Hypertension | 3,190 (36%) | 2,109 (36%) | 1,081 (35%) | 0.3004 | |
|
| 6,651 (74%) | 4,043 (70%) | 2,518 (82%) | <0.0001 | |
|
| 2,268 (26%) | 1,603 (28%) | 665 (22%) | <0.0001 | |
|
| 610 (7%) | 428 (7%) | 182 (6%) | 0.0106 |
AIDS = acquired immune deficiency syndrome; HIV = human immunodeficiency syndrome; SD = standard deviation
Note: Priority 1 veterans are 50%–100% disabled by a military service-related condition and have no co-pays for care or prescription medications; Priority 2–6 veterans have medication co-pays; Priority 7–8 veterans have agreed to pay co-pays for care and medications and are ineligible under Priorities 1–6.
Note: Charlson score defines HIV/AIDS using ICD-9-CM code 042 and does not include asymptomatic HIV infection (ICD-9-CM code V08)
Retention measures at 24 months.
| Variables, n (%) | Cohort (n = 8,845) |
|---|---|
|
| 3,567 (40%) |
|
| 5,786 (65%) |
|
| 4,958 (56%) |
|
| 7,166 (81%) |
Patient outcomes at 24 months.
| Variables | Subcategory | Cohort (n = 8,845) |
|---|---|---|
|
| Suppressed (<500 copies/mL) | 7,235 (82%) |
| Not suppressed (≥ 500 copies/mL) | 1,610 (18%) | |
|
| <200 cells/mm3 | 1,101 (12%) |
| 200–349 cells/mm3 | 1,680 (19%) | |
| 350–500 cells/mm3 | 2,015 (23%) | |
| >500 cells/mm3 | 4,049 (46%) | |
|
| 1,581/2,284 (69%) | |
|
| 853/6,577 (13%) | |
|
| 4,249 (48%) | |
|
| 1.5 ± 3.0 | |
|
| 2,494 (28%) | |
|
| 0.8 ± 1.9 | |
|
| 26 (0.3%) |
*Patients who had these characteristics at baseline were excluded from these results.
ED = emergency department; ART = antiretroviral therapy; AIDS = acquired immune deficiency syndrome; SD = standard deviation
Multivariable nominal logistic regression models for patient outcomes at 24 months: OR (p-value), n = 8,845 , , .
| Retention Measures, adjusted OR (95% CI) | Viral Load <500 copies/mL | CD4 Count >500 cells/mm3 | ART | AIDS | All-Cause ED Visit | All-Cause Hospitalization |
|---|---|---|---|---|---|---|
| Annual Appointments |
|
|
| 0.88 (0.1414) | 0.96 (0.3716) | 1.04 (0.5279) |
| Missed Appointments |
|
|
|
|
|
|
| Infrequent Appointments |
| 0.97 (0.6948) |
| 0.95 (0.5492) | 0.95 (0.2713) | 0.92 (0.1441) |
| Missed or Infrequent Appointments |
| 0.84 (0.0572) |
| 1.15 (0.1945) |
|
|
aCovariates were: patient age, sex, race, marital status, priority group, baseline viral load, baseline CD4 count, Charlson comorbidity score, and treatment facility.
bPatients with outcome of interest at baseline were excluded from these analyses
cBold indicates statistical significance
AIDS = progression to acquired immune deficiency syndrome; ED = emergency department; ART = antiretroviral therapy initiation